Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers
G. Sotiropoulos (Athens, Greece), M. Kotopouli (Athens, Greece), I. Karampela (Athens, Greece), G. Christodoulatos (Athens, Greece), G. Antonakos (Athens, Greece), I. Marinou (Athens, Greece), E. Vogiatzakis (Athens, Greece), A. Lekka (Athens, Greece), A. Papavassiliou (Athens, Greece), M. Dalamaga (Athens, Greece)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Session: Biology and prognosis of lung cancer
Session type: Thematic Poster
Number: 3058
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Sotiropoulos (Athens, Greece), M. Kotopouli (Athens, Greece), I. Karampela (Athens, Greece), G. Christodoulatos (Athens, Greece), G. Antonakos (Athens, Greece), I. Marinou (Athens, Greece), E. Vogiatzakis (Athens, Greece), A. Lekka (Athens, Greece), A. Papavassiliou (Athens, Greece), M. Dalamaga (Athens, Greece). Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers. 3058
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Hypoxia-response gene signatures as predictive and prognostic biomarkers in advanced non-squamous non-small cell lung cancer patients Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Analysis of surgical stage lung cancer and tumour markers prognostic value Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
Nuclear and microenvironment interactions could be useful biological prognostic markers for adjuvant therapy in advanced non-small cell lung carcinoma Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002
Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010
Serum angiopoietins as a clinical marker for resected early lung cancer Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Circulating biomarkers and tumour molecular profiling in patients with non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron- specific enolase in patients with advanced non-small-cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019